Rapidly Progressive Renal Failure in a Young Woman. Scarpelli DG (1975) N Engl J Med 293: 922-7 APOL1 risk variants, race, and progression of chronic kidney disease. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ, AASK Study Investigators, CRIC Study Investigators (2013) N Engl J Med 369: 2183-96 Hemodialysis. Himmelfarb J, Ikizler TA (2010) N Engl J Med 363: 1833-45 Intensive blood-pressure control in hypertensive chronic kidney disease. Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X, AASK Collaborative Research Group (2010) N Engl J Med 363: 918-29 Rational use of analgesic and antiinflammatory drugs. Crofford LJ (2001) N Engl J Med 345: 1844-6 Dialysis and transplantation in end-stage lupus nephritis. Ziff M, Helderman JH (1983) N Engl J Med 308: 218-9 Increased lipid peroxidation in patients with rhabdomyolysis. Holt S, Reeder B, Wilson M, Harvey S, Morrow JD, Roberts LJ, Moore K (1999) Lancet 353: 1241 Toward a unified theory of renal progression. Harris RC, Neilson EG (2006) Annu Rev Med 57: 365-80 Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V (2012) J Am Coll Cardiol 60: 2372-9 Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics. Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I (1980) Ann Intern Med 93: 62-89 Drug therapy in renal failure: dosing guidelines for adults. Part II: sedatives, hypnotics, and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents. Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I (1980) Ann Intern Med 93: 286-325 Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, Ahn S, Kato H, Pullman J, Gessler M, Haase VH, Susztak K (2010) J Clin Invest 120: 4040-54 Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. Pupim LB, Flakoll PJ, Brouillette JR, Levenhagen DK, Hakim RM, Ikizler TA (2002) J Clin Invest 110: 483-92 "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. Yoshioka T, Shiraga H, Yoshida Y, Fogo A, Glick AD, Deen WM, Hoyer JR, Ichikawa I (1988) J Clin Invest 82: 1614-23 Hold tight or you'll fall off: CD151 helps podocytes stick in high-pressure situations. Pozzi A, Zent R (2012) J Clin Invest 122: 13-6 Why is the mortality of dialysis patients in the United States much higher than the rest of the world? Foley RN, Hakim RM (2009) J Am Soc Nephrol 20: 1432-5 Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) J Am Soc Nephrol 20: 872-81 Spontaneous dietary protein intake during progression of chronic renal failure. Ikizler TA, Greene JH, Wingard RL, Parker RA, Hakim RM (1995) J Am Soc Nephrol 6: 1386-91 Digoxin associates with mortality in ESRD. Chan KE, Lazarus JM, Hakim RM (2010) J Am Soc Nephrol 21: 1550-9 Ferric citrate controls phosphorus and delivers iron in patients on dialysis. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group (2015) J Am Soc Nephrol 26: 493-503 Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) J Am Soc Nephrol 20: 2223-33 Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. Becker BN, Fuchs H, Hakim R (1995) J Am Soc Nephrol 5: 1746-50 Low health literacy associates with increased mortality in ESRD. Cavanaugh KL, Wingard RL, Hakim RM, Eden S, Shintani A, Wallston KA, Huizinga MM, Elasy TA, Rothman RL, Ikizler TA (2010) J Am Soc Nephrol 21: 1979-85 Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. Pupim LB, Flakoll PJ, Ikizler TA (2004) J Am Soc Nephrol 15: 1920-6 Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. Chan KE, Warren HS, Thadhani RI, Steele DJ, Hymes JL, Maddux FW, Hakim RM (2012) J Am Soc Nephrol 23: 1551-9 Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M, Feldman H, Gassman J, Lea J, Kopple J, Sika M, Toto R, Greene T (2006) J Am Soc Nephrol 17: 2900-9 Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. Lacson E, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, Lester K, Ofsthun N, Lazarus M, Hakim RM (2012) J Am Soc Nephrol 23: 687-95 A multi-marker approach to predict incident CKD and microalbuminuria. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS (2010) J Am Soc Nephrol 21: 2143-9 Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW (1991) J Am Soc Nephrol 2: 1130-5 Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. Wang XP, Fogo AB, Colon S, Giannico G, Abul-Ezz SR, Miner JH, Borza DB (2005) J Am Soc Nephrol 16: 3563-71 Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J (2008) J Am Soc Nephrol 19: 593-9 Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. Ikizler TA (2008) J Am Soc Nephrol 19: 1059-62 Sodium intake, ACE inhibition, and progression to ESRD. Luther JM (2012) J Am Soc Nephrol 23: 10-2 Chronic kidney disease progression. Eddy AA, Neilson EG (2006) J Am Soc Nephrol 17: 2964-6 Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. Himmelfarb J, Ikizler TA, Ellis C, Wu P, Shintani A, Dalal S, Kaplan M, Chonchol M, Hakim RM (2014) J Am Soc Nephrol 25: 623-33 A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT, AASK Study Group (2004) J Am Soc Nephrol 15: 3175-83 Allograft nephrectomy after transplant failure: should it be performed in all patients returning to dialysis? Schaefer HM, Helderman JH (2010) J Am Soc Nephrol 21: 207-8 Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ (2012) J Am Soc Nephrol 23: 334-42 CKD classification: time to move beyond KDOQI. Ikizler TA (2009) J Am Soc Nephrol 20: 929-30 Oxidative stress is increased in critically ill patients with acute renal failure. Himmelfarb J, McMonagle E, Freedman S, Klenzak J, McMenamin E, Le P, Pupim LB, Ikizler TA, The PICARD Group (2004) J Am Soc Nephrol 15: 2449-56
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.